Tenofovir alafenamide: all 136 studies that test it
Page 2 of 2. Open to participants first (23), then studies with results posted, then the rest; newest registration first within each.
- Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed AdultsStatus unknownNCT04311957Phase 4
- Biktarvy in Treatment-Naïve Late Presenters With HIV-1 InfectionCompletedNCT04296695Phase 4
- Tenofovir Alafenamide(TAF) Reduces the Risk of Hepatocellular Carcinoma(HCC) RecurrenceStatus unknownNCT04290936Phase 4
- Rapid Start vs. Standard Start Antiretroviral Therapy (ART) in HIVTerminatedNCT04249037Phase 4
- A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat When Administered as a Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared to the Co-administration of the Separate AgentsTerminatedNCT04236453Phase 1
- Efficacy and Safety of TAF in Patients With Suboptimal Response to Other Nucleos(t)IdesStatus unknownNCT04201808Phase 4
- Three Types of Nucleotide/Nucleoside Analogues Therapy in Patients With Hepatitis b Virus Related Compensated CirrhosisStatus unknownNCT04196998Not applicable
- Three Types of Nucleotide/Nucleoside Analogues Therapy in Patients With Chronic Hepatitis bStatus unknownNCT04195074Not applicable
- Neurological Monitoring in Patients Switching From Dolutegravir Based Regimen to Bictegravir Based RegimenStatus unknownNCT04155554Phase 3
- Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Marginalized Populations Who Are Virologically SuppressedStatus unknownNCT04132674Phase 4
- Tenofovir Alafenamide With Fine Needle Aspiration Biopsy in Chronic Hepatitis B:Status unknownNCT04070079Phase 4
- A Perspective Study of the Antiviral Efficacy and Safety of Switching to TAF Treatment in CHB Adults With Suboptimal Response (SOR) and Intolerant to EntecavirStatus unknownNCT04034368Phase 4
- BONE: STAR (Switching to TAF Based Anti-Retroviral Therapy) StudyStatus unknownNCT03916328Phase 4
- The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir AlafenamideTerminatedNCT03804372Phase 2
- TAF Switch in F3/4 CHB pt With Partial Response to NUC (ESTAB-AFPVR)Status unknownNCT03798119Phase 4
- Effectiveness of TAF in Reducing Clinical Events in CHB Patients Beyond Treatment Indications by Current GuidelinesActive, not recruitingNCT03753074Phase 4
- Maternal Screening and Antiviral Therapy in Pregnant Women to Reduce Mother-to-infant Transmission of Hepatitis B VirusStatus unknownNCT03695029Phase 4
- Efficacy, Safety & Tolerability of Switching EFV/TDF/FTC to BIC/FTC/TAF in Virologically Suppressed Adults With HIV-1CompletedNCT03502005Phase 4
- Entecavir to TAF SwitchActive, not recruitingNCT03489239Phase 3
- Same-Day Treatment With Genvoya vs. EFV/TDF/3TCWithdrawnNCT03405194Not applicable
- Change of Renal Function and Bone Mineral Density in CHB Patients Switch From TDF to TAF vs. Maintaining TDFCompletedNCT03356834Phase 4
- ADVANCE Study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in First-line Antiretroviral TherapyCompletedNCT03122262Phase 3
- TAF for HIV-HBV With Renal DysfunctionCompletedNCT03115736Phase 2
- Changes in Insulin Sensitivity in Healthy Volunteers Taking Tenofovir Alafenamide (TAF)-Containing Antiretroviral MedicationCompletedNCT03092206Phase 1
- Study to Evaluate the Relative Bioavailability of Fixed-dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) as a Whole Tablet, as a Split Tablet, and as Crushed Tablet in Healthy Adult ParticipantsCompletedNCT02984852Phase 1
- TAF Switch Study in Hepatitis B MonoinfectionStatus unknownNCT02957994Phase 4
- Switching From Tenofovir Disoproxil Fumarate to Abacavir or Tenofovir AlafenamideStatus unknownNCT02957864Phase 4
- Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus InfectionActive, not recruitingNCT02932150Phase 2
- PK and PD Study of Oral F/TAF for HIV PreventionCompletedNCT02904369Phase 1
- Tenofovir Alafenamide Fumarate (TAF) Effect on Residual Intrathecal Immune ActivationCompletedNCT02771054Phase 4
- A Bioequivalence Study of Darunavir, Emtricitabine, and Tenofovir Alafenamide, in the Presence of Cobicistat in Healthy ParticipantsCompletedNCT02578550Phase 1
- Relative Bioavailability and Food Effect for Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed Dose CombinationCompletedNCT02475135Phase 1
- Dose Proportionality of TFV-DP After a Single Dose of GS-7340 in WomenCompletedNCT02357602Phase 1
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIVActive, not recruitingNCT02016924Phase 2/3
- A Phase 1b Study Assessing GS-7340 in Treatment-Naive Adults With Chronic Hepatitis BCompletedNCT01671787Phase 1
- A Dose Escalation Study of Tenofovir Alafenamide in Treatment-Naive PatientsCompletedNCT00036634Phase 1/2